Pictet Asset Management Holding SA Sells 268,937 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Pictet Asset Management Holding SA cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 36.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 471,573 shares of the biotechnology company’s stock after selling 268,937 shares during the period. Pictet Asset Management Holding SA owned 0.19% of BioCryst Pharmaceuticals worth $4,459,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Phocas Financial Corp. bought a new position in BioCryst Pharmaceuticals in the 4th quarter worth $1,956,000. Aberdeen Group plc bought a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at about $7,126,000. Vanguard Group Inc. grew its holdings in BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the period. BNP Paribas Financial Markets increased its position in BioCryst Pharmaceuticals by 21.4% in the fourth quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock worth $19,833,000 after buying an additional 448,436 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in BioCryst Pharmaceuticals by 106.5% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock worth $1,820,000 after buying an additional 120,350 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on BCRX shares. Needham & Company LLC decreased their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Citizens Jmp boosted their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Cantor Fitzgerald raised their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.67.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $9.84 on Friday. The firm has a market cap of $2.50 billion, a P/E ratio of -5.53 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $10.94. The company has a 50 day simple moving average of $8.96 and a two-hundred day simple moving average of $8.33.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. During the same period last year, the firm posted $0.20 EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.63 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.